Medicamen Biotech per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹7.41₹7.22₹5.16₹7.50₹11.82
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹7.41₹7.22₹5.16₹7.50₹11.82
₹203.17₹203.17₹167.35₹157.68₹152.88
₹149.40₹145.82₹127.84₹141.02₹111.35
—−₹24.46−₹5.66−₹0.29−₹4.97
−₹27.98−₹27.98−₹7.29−₹5.23−₹10.19
—₹1.00₹1.00₹0.99₹1.00
1.41.41.31.31.3
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

MEDICAMEQ₹254.25

Medicamen Biotech Limited

· Pharma & Health
₹ CrorePeersMEDICOAAREYDRUGSNECLIFEHALEOSLABSALBERTDAVDNATCAPSUQVALIANTLABBALPHARMAMcap ₹345 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS11.827.505.167.227.41
Diluted EPS11.827.505.167.227.41
Book Value per Share152.88157.68167.35203.17203.17
Revenue per Share111.35141.02127.84145.82149.40
Cash Flow per Share-4.97-0.29-5.66-24.46—
Free Cash Flow per Share-10.19-5.23-7.29-27.98-27.98
Dividends per Share1.000.991.001.00—
Shares Outstanding (cr)1.31.31.31.41.4
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.